Danish pharmaceutical group Novo, formerly Novo Nordisk and best known for Ozempic, has partnered with Anthropic to accelerate drug development using artificial intelligence.
AI Expands Into Novo’s R&D
Under the agreement, Novo will use Anthropic’s models and Claude Science across its research and development operations. The company said the tools will support scientific reasoning, improve productivity and help researchers explore new approaches to understanding human biology and drug mechanisms.
Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram
“Joining forces with Anthropic will supercharge our R&D organisation and help us on our mission to bring new, transformative health solutions to people living with chronic diseases,” Novo President and CEO Mike Doustdar said in a press release.
Anthropic CEO Dario Amodei said access to advanced AI models could help researchers shorten research timelines and improve drug discovery.
Novo Builds A Broader AI Strategy
The Anthropic partnership follows Novo’s separate agreement with OpenAI in April to use AI for analyzing complex datasets, identifying potential drugs and reducing the time between research and patient access.
Novo is also involved in Denmark’s AI infrastructure. In 2024, the Novo Nordisk Foundation partnered with Nvidia and the Export and Investment Fund of Denmark to establish the Danish Centre for AI Innovation, which operates the Gefion supercomputer.
Anthropic Expands In Life Sciences
Anthropic has also been expanding its presence in healthcare and pharmaceuticals. In May 2026, it announced a collaboration with Bristol Myers Squibb covering research, clinical development, manufacturing, commercial and corporate functions.
The Novo partnership adds another major pharmaceutical company to Anthropic’s life sciences business as drugmakers increasingly apply AI to research and development.







